Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells
Angewandte Chemie International Edition · 2024-10 · 63 (40)
DOI: 10.1002/anie.202410791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 19.08.2024. Verfasst von Lucrezia Cosottini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry "Ugo Schiff", University of Florence, 50019, Sesto Fiorentino, FI, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ferritins, Ovarian Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Aurothiomalate (AuTM) is an FDA‐approved antiarthritic gold drug with unique anticancer properties. To enhance its anticancer activity, we prepared a bioconjugate with human apoferritin (HuHf) by attaching some AuTM moieties to surface protein residues. The reaction of apoferritin with excess AuTM yielded a single adduct, that was characterized by ESI MS and ICP‐OES analysis, using three mutant ferritins and trypsinization experiments. The adduct contains ~3 gold atoms per ferritin subunit, arranged in a small cluster bound to Cys90 and Cys102. MD simulations provided a plausible structural model for the cluster. The adduct was evaluated for its pharmacological properties and was found to be significantly more cytotoxic than free AuTM against A2780 cancer cells mainly due to higher gold uptake. NMR‐metabolomics showed that AuTM bound to HuHf and free AuTM induced qualitatively similar changes in treated cancer cells, indicating that the effects on cell metabolism are approximately the same, in agreement with independent biochemical experiments. In conclusion, we have demonstrated here that a molecularly precise bioconjugate formed between AuTM and HuHf exhibits anticancer properties far superior to the free drug, while retaining its key mechanistic features. Evidence is provided that human ferritin can serve as an excellent carrier for this metallodrug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry "Ugo Schiff", University of Florence, 50019, Sesto Fiorentino, FI, Italy.
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.
- Consorzio Interuniversitario Risonanze Magnetiche di Metallo Proteine (CIRMMP), 50019, Sesto Fiorentino, FI, Italy.
- Magnetic Resonance Center, University of Florence, 50019, Sesto Fiorentino, FI, Italy.
ORCID-Profile: Luigi Messori
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Cosottini, L., Geri, A., Ghini, V., Mannelli, M., Zineddu, S., Di Paco, G., Giachetti, A., Massai, L., Severi, M., Gamberi, T., Rosato, A., Turano, P., & Messori, L. (2024). Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells. Angewandte Chemie International Edition, 63(40). https://doi.org/10.1002/anie.202410791
Vancouver
Cosottini L, Geri A, Ghini V, Mannelli M, Zineddu S, Di Paco G, et al. Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells. Angewandte Chemie International Edition. 2024;63(40). doi:10.1002/anie.202410791
BibTeX
@article{Cosottini2024,
author = {Cosottini, Lucrezia and Geri, Andrea and Ghini, Veronica and Mannelli, Michele and Zineddu, Stefano and Di Paco, Giorgio and Giachetti, Andrea and Massai, Lara and Severi, Mirko and Gamberi, Tania and Rosato, Antonio and Turano, Paola and Messori, Luigi},
title = {Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {40},
doi = {10.1002/anie.202410791}
}
EUVIMED